Related Experiment Videos
Systemic cyclosporine A in severe atopic keratoconjunctivitis
T Hoang-Xuan1, O Prisant, D Hannouche
1Department of Ophthalmology, Hospital Bichat, Paris, France.
Ophthalmology
|August 1, 1997
Summary
Systemic cyclosporine A (CSA) effectively controlled ocular inflammation in most patients with severe atopic keratoconjunctivitis (AKC). This therapy offers a promising alternative for managing this sight-threatening eye condition.
Area of Science:
- Ophthalmology
- Immunology
- Dermatology
Background:
- Atopic keratoconjunctivitis (AKC) is a severe ocular condition often linked to atopic dermatitis.
- Severe AKC can be sight-threatening and may not respond adequately to conventional steroid therapy.
Observation:
- This retrospective study evaluated systemic cyclosporine A (CSA) in four patients with severe AKC and atopic dermatitis.
- Patients were refractory to or dependent on steroid therapy.
Findings:
- Systemic CSA, at dosages of 3-5 mg/kg/day for a mean of 37 months, achieved total ocular inflammation control in three out of four patients.
- One patient showed partial response. Renal toxicity was observed in one patient but resolved upon CSA dose reduction.
Implications:
- Systemic CSA is a viable therapeutic option for severe AKC cases unresponsive to standard treatments.
- Careful monitoring for side effects like renal toxicity is essential during CSA therapy for AKC.